Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Rostambeigi 2011 Transplantation"

From Bioblast
Line 1: Line 1:
{{Publication
{{Publication
|title=Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC (2011) Unique cellular and mitochondrial defects mediate FK506-induced islet Ξ²-cell dysfunction. Transplantation 91:615-23.
|title=Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC (2011) Unique cellular and mitochondrial defects mediate FK506-induced islet Ξ²-cell dysfunction. Transplantation 91:615-23.
|info=[http://www.ncbi.nlm.nih.gov/pubmed/21200364 PMID:21200364 ]
|info=[http://www.ncbi.nlm.nih.gov/pubmed/21200364 PMID: 21200364 Open Access]
|authors=Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC
|authors=Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC
|year=2011
|year=2011
Line 12: Line 12:


'''CONCLUSIONS:''' At pharmacologically relevant concentrations, FK506 decreases insulin secretion and reduces mitochondrial density and function without changing apoptosis rates, suggesting that posttransplantation diabetes induced by FK506 may be mediated by its effects on mitochondrial function.
'''CONCLUSIONS:''' At pharmacologically relevant concentrations, FK506 decreases insulin secretion and reduces mitochondrial density and function without changing apoptosis rates, suggesting that posttransplantation diabetes induced by FK506 may be mediated by its effects on mitochondrial function.
|keywords=FK506, islet toxicity, mitochondrial density, mitochondrial DNA, insulin secretion, motifADE.
|keywords=FK506, Islet toxicity, Mitochondrial density, Mitochondrial DNA, Insulin secretion, motifADE
|mipnetlab=US_MN Rochester_Nair KS, US PA Danville Irving BA
|mipnetlab=US MN Rochester Nair KS, US PA Danville Irving BA
}}
}}
{{Labeling
{{Labeling

Revision as of 15:24, 19 March 2015

Publications in the MiPMap
Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC (2011) Unique cellular and mitochondrial defects mediate FK506-induced islet Ξ²-cell dysfunction. Transplantation 91:615-23.

Β» PMID: 21200364 Open Access

Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC (2011) Transplantation

Abstract: OBJECTIVE: To determine biological mechanisms involved in posttransplantation diabetes mellitus caused by the immunosuppressant tacrolimus (FK506).

METHODS: INS-1 cells and isolated rat islets were incubated with vehicle or FK506 and harvested at 24-hr intervals. Cells were assessed for viability, apoptosis, proliferation, cell insulin secretion, and content. Gene expression studies by microarray analysis, quantitative polymerase chain reaction, and motifADE analysis of the microarray data identified potential FK506-mediated pathways and regulatory motifs. Mitochondrial functions, including cell respiration, mitochondrial content, and bioenergetics were assessed.

RESULTS: Cell replication, viability, insulin secretion, oxygen consumption, and mitochondrial content were decreased (P<0.05) 1.2-, 1.27-, 1.77-, 1.32-, and 1.43-fold, respectively, after 48-hr FK506 treatment. Differences increased with time. FK506 (50 ng/mL) and cyclosporine A (800 ng/mL) had comparable effects. FK506 significantly decreased mitochondrial content and mitochondrial bioenergetics and showed a trend toward decreased oxygen consumption in isolated islets. Cell apoptosis and proliferation, mitochondrial DNA copy number, and ATP:ADP ratios were not significantly affected. Pathway analysis of microarray data showed FK506 modification of pathways involving ATP metabolism, membrane trafficking, and cytoskeleton remodeling. PGC1-Ξ± mRNA was down-regulated by FK506. MotifADE identified nuclear factor of activated T-cells, an important mediator of Ξ²-cell survival and function, as a potential factor mediating both up- and down-regulation of gene expression.

CONCLUSIONS: At pharmacologically relevant concentrations, FK506 decreases insulin secretion and reduces mitochondrial density and function without changing apoptosis rates, suggesting that posttransplantation diabetes induced by FK506 may be mediated by its effects on mitochondrial function. β€’ Keywords: FK506, Islet toxicity, Mitochondrial density, Mitochondrial DNA, Insulin secretion, motifADE

β€’ O2k-Network Lab: US MN Rochester Nair KS, US PA Danville Irving BA


Labels: MiParea: Respiration  Pathology: Diabetes 

Organism: Rat  Tissue;cell: Islet cell;pancreas;thymus  Preparation: Intact cells 

Regulation: ATP; ADP; AMP; PCr"ATP; ADP; AMP; PCr" is not in the list (Aerobic glycolysis, ADP, ATP, ATP production, AMP, Calcium, Coupling efficiency;uncoupling, Cyt c, Flux control, Inhibitor, ...) of allowed values for the "Respiration and regulation" property. 


HRR: Oxygraph-2k